Longitudinal Change in the BODE Index Predicts Mortality in Severe Emphysema

Fernando J. Martinez1, MeiLan K. Han1, Adin-Cristian Andrei2, Robert Wise3, Susan Murray4, Jeffrey L. Curtis3,5, Alice Sternberg6, Gerard Criner6, Steven E. Gay7, John Reilly8, Barry Make9, Andrew L. Ries9, Frank Sciurba10, Gail Weinmann11, Zab Mosenifar12, Malcolm DeCamp13, Alfred P. Fishman14, and Bartolome R. Celli15, for the National Emphysema Treatment Trial Research Group*

Rationale: The predictive value of longitudinal change in BODE (Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) index has received limited attention. We hypothesized that decrease in a modified BODE (mBODE) would predict survival in National Emphysema Treatment Trial (NETT) patients.

Objectives: To determine how the mBODE score changes in patients with lung volume reduction surgery versus medical therapy and correlations with survival.

Methods: Clinical data were recorded using standardized instruments. The mBODE was calculated and patient-specific mBODE trajectories during 6, 12, and 24 months of follow-up were estimated using separate regressions for each patient. Patients were classified as having decreasing, stable, increasing, or missing mBODE based on their absolute change from baseline. The predictive ability of mBODE change on survival was assessed using multivariate Cox regression models. The index of concordance was used to directly compare the predictive ability of mBODE and its separate components.

Measurements and Main Results: The entire cohort (610 treated medically and 608 treated surgically) was characterized by severe airflow obstruction, moderate breathlessness, and increased mBODE at baseline. A wide distribution of change in mBODE was seen at follow-up. An increase in mBODE of more than 1 point from baseline to 6, 12, and 24 months of follow-up was predictive of subsequent mortality. Increase in mBODE of more than 1 point was associated with increased mortality. Change in modified BODE may prove a good surrogate measure of survival in therapeutic trials in severe chronic obstructive pulmonary disease.

Conclusions: The mBODE demonstrates short- and intermediate-term responsiveness to intervention in severe chronic obstructive pulmonary disease. Increase in mBODE of more than 1 point from baseline to 6, 12, and 24 months of follow-up was predictive of subsequent mortality. Change in mBODE may prove a good surrogate measure of survival in therapeutic trials in severe chronic obstructive pulmonary disease.

What This Study Adds to the Field

In a cohort of patients with severe emphysema, an increase in modified BODE of more than 1 is associated with increased mortality. Change in modified BODE also predicted survival better than its separate components.

* A complete listing of NETT Research Group members can be found before the references.

Received in original form September 18, 2007; accepted in final form June 4, 2008

The National Emphysema Treatment Trial (NETT) was supported by contracts with the National Heart, Lung, and Blood Institute (N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, and N01HR76119), the Centers for Medicare and Medicaid Services (formerly the Health Care Financing Administration), and the Agency for Healthcare Research and Quality. J.L.C. is supported by funding from a Research Enhancement Award Program (REAP) from the Biomedical Laboratory Research and Development Service, Department of Veterans Affairs.

Originaly Published in Press as DOI: 10.1164/rccm.200709-1383OC on June 5, 2008

Internet address: www.atsjournals.org

AT A GLANCE COMMENTARY

Scientific Knowledge on the Subject

The BODE index has prognostic value with respect to chronic obstructive pulmonary disease mortality, although the importance of change in BODE has received limited attention.

What This Study Adds to the Field

In a cohort of patients with severe emphysema, an increase in modified BODE of more than 1 is associated with increased mortality. Change in modified BODE also predicted survival better than its separate components.

Modifying disease in chronic obstructive pulmonary disease (COPD) has become an increasingly feasible therapeutic option in patients with COPD. Decreasing mortality is particularly important in this disorder, which has exhibited a rising mortality over the past several decades (1). Clinical treatments that seek to improve mortality in COPD require large populations studied for long periods. A recently completed pharmacologic intervention resulted in a modest trend to improved survival despite more than 6,000 patients randomized to four treatment arms (2). It is very desirable to have a “marker” that can be used as a surrogate for survival to circumvent the need for large or prolonged trials. One such measure, the multidimensional BODE (Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) index, has recently been shown to predict survival in cohort studies of COPD (3, 4). However, for a surrogate outcome to be valid, two other conditions should be satisfied. First, the measure should be responsive to treatments that improve survival. Second, the
measure should show a dose–response relationship—that is, those patients who show the greatest improvement have the greatest increase in survival and those who show the least improvement (or greatest worsening) should have the greatest decrease in survival. The BODE index has partially satisfied the first of these conditions in an uncontrolled study of rehabilitation (5) and in three uncontrolled studies of lung volume reduction surgery (LVRS) (6–8). Moreover, those patients who demonstrated greater decreases in BODE index tended to have the best survival. Because these studies were uncontrolled, however, it is possible that these results could have reflected, in part, the natural variation in disease over time rather than the effect of therapeutic interventions alone.

The National Emphysema Treatment Trial (NETT) provides an ideal dataset to examine the relationship of changes in BODE index to survival insofar as it compares an active intervention (LVRS) with maximal medical therapy in a randomized trial of patients with severe COPD. The modified BODE (mBODE) has previously been shown to be a good predictor of survival in the NETT population (4). We hypothesized that the NETT population would allow a clear definition of the natural history of BODE, and that the wide distribution of longitudinal changes in BODE would allow a more clearly defined assessment of the magnitude of change that reliably predicts subsequent mortality. In the present analysis, the predefined specific goals were to answer the following questions:

- Does the mBODE score improve with LVRS more than maximal medical therapy?
- Does an improvement or worsening of mBODE correlate with improved or worsening survival within each treatment group?
- Does the magnitude of change in BODE predict the magnitude of improvement in survival?

**METHODS**

**Patient Selection**

The study group consisted of all patients randomized to medical or surgical therapy at 17 NETT clinics (9). The design and methods of the trial have been previously detailed (9, 10). All patients provided written, informed consent, and the institutional review board at each clinic approved the study. Baseline measurements were completed after informed consent, and the institutional review board at each clinic approved the study. Baseline vital signs, demographic data, and smoking and medical history were collected by patient interview using standardized instruments. Dyspnea was quantified using the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) (11).

**Physiologic Testing**

Patients underwent spirometry and plethysmographic lung volume measurement after the administration of albuterol; diffusing capacity, respiratory pressures, and arterial blood gases were also measured. The protocol used for six-minute-walk testing (6MWT) has been described in detail and provided the maximal distance walked (12).

**Modified BODE**

The BODE index is an 11-point composite score (0 through 10) in which higher scores indicate poorer outcomes (3). We modified the original BODE by using the UCSD SOBQ as the dyspnea measure because the Medical Research Council dyspnea scale was not used in NETT; this modified BODE demonstrated similar predictive ability in patients with severe emphysema (4).

**Statistical Analysis**

Means of mBODE over time were estimated and tested using the mixed models framework, which adjusts for bias due to patients being lost to attrition over time. Patient-specific mBODE trajectories were estimated using individual linear regressions applied to data available from randomization to 6, 12, or 24 months. For patients surviving beyond each of these times the estimated absolute change in mBODE from baseline was obtained. Vital status was assessed by review of records at each institution and supplemented by the use of the Social Security Death Master File ensuring complete capture of data.

On the basis of the absolute change in mBODE at 6, 12, and 24 months elapsed since randomization and available data, patients were classified into four distinct groups at each time point: (1) mBODE decreased by greater than 1 point, (2) mBODE remains stable, (3) mBODE increased greater than 1 point, (4) data missing for mBODE calculation. Survival was estimated both within each treatment arm and in the overall cohort, on the basis of multivariate Cox regression models, while adjusting for sex, ethnicity, baseline age, and baseline mBODE. To assess the Cox model fit and to directly compare mBODE mortality predictive power with that of each of its components, the index of concordance was computed. This measures model fit by calculating the percentage of times observed mortality pairs are correctly ordered by the model. Higher values are reflective of increasingly better model fit.

**RESULTS**

The entire cohort was characterized by elderly patients with severe airflow obstruction, moderate breathlessness, and increased mBODE (Table 1). At baseline, there were no differences in mBODE between the medical and surgical arms. Tables 2 and 3 give insight into the magnitude of mBODE differences between the two treatment arms over time and formally compare the two arms based on mixed model results that adjust for attrition of repeated measures. As shown in Table 3, surviving surgically treated (LVRS) patients presented negative slopes at 6, 12, and 24 months postrandomization on average, whereas medically treated patients had significantly higher (P value always less than 0.001) positive mBODE slopes at each time point.

Among those who survived to 6, 12, and 24 months postrandomization (Table E1), subtle differences were observed in component variables of the mBODE at baseline in both the medical and surgical groups, making formal treatment comparisons among survivors over time inappropriate. When patients were grouped by survival duration, there was a clear gradient in baseline FEV1 and baseline dyspnea, with those who survived 24 months having higher FEV1 and lower dyspnea at baseline than those who did not survive as long.

The influence of changes in mBODE on subsequent mortality was assessed by computing individual trajectories on the basis of each patient’s available mBODE patient history available at 6 (Figure 2), 12 (Figure E2), and 24 months (Figure E2) postrandomization. The mortality characteristics of the entire cohort (Figure 2A), surgically treated patients (Figure 2B), and medically treated patients (Figure 2C) 6 months after randomization are illustrated in Figure 2 by prior change in mBODE. Similar
A decrease in mBODE of greater than 1 point was associated with a significantly increased mortality (HR, 2.35; 95% CI, 1.71–3.23; P < 0.001). Patients with missing data at 6 months experienced an intermediate increase in mortality (HR, 1.45; 95% CI, 1.10–1.92; P = 0.01). Similar results were noted in the entire cohort at 12 and 24 months postrandomization. In the surgically treated cohort, a decrease in mBODE of more than 1 point at 6 months was suggestive of improved subsequent survival (HR, 0.72; 95% CI, 0.48–1.08; P = 0.110), with a similar trend at 12 and 24 months postrandomization becoming statistically significant. Hazards associated with an increase in mBODE of greater than 1 point or missing data were somewhat higher in the surgical arm compared with the medical arm; otherwise, hazards in both treatment arms were ordered very similarly to the overall cohort and were highly statistically significant. An exploratory analysis confirmed that a change of 1 point in mBODE better distributed survival curves than other thresholds, including a 2-point change in mBODE (data not shown).

Figure 4 illustrates event-free rates associated with the composite outcome of death or an increase in mBODE of more than 1 point. The median time to this composite event was significantly shorter in medically treated patients (3.65 yr; 95% CI, 3.21–4.37 yr) compared with LVRS-treated patients (5.68 yr; 95% CI, 4.93 yr–not available). Table 4 demonstrates indices of concordance for mBODE, 6MWT, and UCSD SOBQ. The index of concordance allows us to quantify the predictive ability of a survival model. As can be seen from the table, mBODE exhibits indices of concordance consistently higher than those obtained for FEV₁, 6MWT distance, and the UCSD SOBQ alone, indicating that the predictive ability of the mBODE for survival is better than any of the individual components. On the other hand, it appears that change in UCSD SOBQ likely accounted for much of the mBODE’s predictive ability.

**DISCUSSION**

Reducing mortality has become increasingly feasible in COPD. Therapeutic trials designed to demonstrate improved survival require large study design with prolonged periods of follow-up. As such, identifying reliable surrogates of survival in COPD has become an important concept. Multidimensional indices, such as the BODE index, evaluated at baseline have been shown to exhibit greater predictive values than the individual components of the index. Recently, three uncontrolled studies have suggested that the BODE index changes after therapeutic intervention and that this change appears to relate to subsequent mortality (5, 6). These studies have been limited by lack of control groups. The current analysis describes longitudinal curves for 12 and 24 months after randomization are illustrated in Figure E2. It is evident that there are distinct groups with significantly different survival experiences in the entire cohort, in surgically treated patients, and in medically treated patients. Figure 3 illustrates how a decrease in mBODE of greater than 1 point at 6 months postrandomization in the entire cohort was associated with a significant increase in subsequent mortality (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.41–0.78; P < 0.001), whereas an increase in mBODE of more than 1 point was associated with a significantly increased mortality (HR, 5.18; 95% CI, 3.21–8.73; P < 0.001). Similar results were noted in other thresholds, including a 2-point change in mBODE (data not shown).

**TABLE 2. MEAN (SD) mBODE INDEX IN MEDICALLY TREATED AND LUNG VOLUME REDUCTION SURGERY PATIENT GROUPS AT 6, 12, AND 24 MONTHS POSTRANDOMIZATION**

<table>
<thead>
<tr>
<th>Time Since Randomization</th>
<th>Entire Cohort (n)</th>
<th>Medical Arm (n)</th>
<th>LVRS Arm (n)</th>
<th>T Value</th>
<th>df</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Months</td>
<td>881</td>
<td>460 (1.44)</td>
<td>421</td>
<td>5.07 (1.41)</td>
<td>469</td>
<td>4.18 (1.33)</td>
</tr>
<tr>
<td>12 Months</td>
<td>711</td>
<td>5.43 (1.51)</td>
<td>737</td>
<td>5.13 (1.44)</td>
<td>384</td>
<td>3.84 (1.30)</td>
</tr>
<tr>
<td>24 Months</td>
<td>587</td>
<td>4.12 (1.65)</td>
<td>260</td>
<td>5.23 (1.35)</td>
<td>327</td>
<td>3.24 (1.29)</td>
</tr>
</tbody>
</table>

*Definition of abbreviations: df = degrees of freedom; LVRS = lung volume reduction surgery; mBODE = modified BOED (Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) index.*

Results are based on mixed model adjusting for patient sex, ethnicity, baseline age, and baseline mBODE.
changes in a highly characterized, large cohort of patients with severe emphysema, half of whom underwent a therapeutic intervention that resulted in significant improvement. As such, we report the following: (1) the mBODE is responsive to longitudinal changes with greater improvement in surgically compared with medically treated patients; (2) a decrease in mBODE of more than 1 point was predictive of lesser mortality in the entire cohort and, particularly, the surgically treated cohort; (3) an increase of mBODE of more than 1 point was predictive of greater mortality, a finding more consistently seen in the medically treated patients; (4) analysis of concordance suggests that the mBODE is more predictive of survival than the changes in its individual components; and (5) short-term changes in a composite index can be used to define expected changes in mBODE in future COPD studies.

We confirm that the mBODE changes over 6 to 24 months in patients with severe COPD. Interestingly, the entire cohort illustrated similar numbers of patients who exhibited increases or decreases in mBODE. Importantly, medically treated patients appeared to experience a lesser change in mBODE, with most of the change seen in increasing values, suggesting a worsening score in this multidimensional index. A separate report noted similar, subtle change in BODE in a cohort of patients, some of whom were treated with pulmonary rehabilitation (5). Although the influence of additional pulmonary rehabilitation in the current cohort cannot be directly assessed, our work expands previous data by providing insight into the natural history of longitudinal change in mBODE in a large cohort of patients with severe emphysema treated with maximal medical therapy. Furthermore, these data allow the calculation of the expected natural history of the mBODE in such patients over a 2-year time frame. These data can be used to define expected changes in mBODE in future therapeutic trials that wish to use this composite index as a treatment outcome.

Our data provide a contrast in that surgically treated patients exhibit a wider distribution of changes in scores, with a larger number of patients experiencing decreasing, or improving, scores. These data expand on the original observations of the NETT that confirmed functional improvements in surgically compared with medically treated patients with severe emphysema (9). Two groups have recently presented results of short-term (3 mo) and intermediate-term (12–24 mo) changes in BODE in a small group of patients with emphysema treated with LVRS that document a similar distribution of change, with the majority of patients exhibiting decreases in scores (6–8). Our data extend these observations by illustrating the natural history of change in mBODE over a 2-year period, and are strengthened by having a similar medically treated patient group for comparison. Direct survival comparison of surgically versus medically treated patients by mBODE change is limited by differential mortality over the period of measurements. Nevertheless, the totality of these data provides insight into the potential change in mBODE in patients with severe COPD treated with a therapy that provides marked functional improvements.

Our data provide important insight into how short- and intermediate-term changes in a composite index can be used to predict mortality in a large group of medically and surgically treated patients with severe COPD. In both medically and surgically treated patients, an increase in mBODE was associated with an increased risk of mortality in subsequent follow-up. This was noted as early as 6 months and out to 2 years after randomization to intervention. Furthermore, a greater than 1 point increase in mBODE was associated with a 1.9- to 2.1-fold increase in mortality in medically treated patients and a 2.5- to 3.6-fold increase in surgically treated patients. We also noted that a decrease in mBODE of greater than 1 point after 12 months was associated with improved subsequent mortality only in surgically treated patients. These data expand on results from other groups that suggest that a decrease in BODE is associated with decreased subsequent mortality in surgically treated patients (6) by illustrating that changes in mBODE are predictive of subsequent mortality from as short as 6 months of follow-up to 24 months of follow-up. An important finding of our study is the ability to

![Figure 1](image-url)  The percentage of patients (x axis) experiencing changes in mBODE (modified Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) (y axis) 6 months after randomization to medical therapy or bilateral lung volume reduction surgery (LVRS). Patients who had died or were not able to provide data to calculate mBODE at each time point are also illustrated.
describe the time to death or to an increase in mBODE in medically and surgically treated patients. These data can be used to construct clinical trials of therapeutic interventions that may improve mortality with a smaller sample size over a period as short as 6 months.

We also provide insight into the operating characteristics of a composite index in contrast to some of the individual components. An analysis of concordance demonstrates that the composite index was better able to predict subsequent mortality in the entire cohort as well as in the medically and surgically treated patients. A higher index of concordance was evident for the composite mBODE index at 6, 12, and 24 months after intervention. Further examination suggests that the majority of change in mBODE was contributed by improved dyspnea. Our

Figure 2. Kaplan-Meier survival curves (starting at 6 months after randomization [F06]) for the entire cohort (A), surgically treated patients (lung volume reduction surgery [LVRS] arm) (B), and medically treated patients (C) in patients who survived and were able to provide data to calculate mBODE (modified Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) 6 (F06) months after randomization. Survival curves are segregated by groups who experienced a decrease in mBODE > 1 (blue), a rise in mBODE > 1 (red), no change in mBODE (−1 to 1 point change) (green), or missing data (black) from baseline to the starting time point. (A) Log rank = 46.9; degrees of freedom = 3; P value < 0.01. (B) Log rank = 53; degrees of freedom = 3; P value < 0.01. (C) Log rank = 7.58; degrees of freedom = 3; P value ≤ 0.06.
data extend the findings of others that have suggested that change in 6MWD over 1 year predicts survival (13) by contrasting change in exercise capacity with longitudinal changes in dyspnea, FEV₁, and a composite index incorporating all of these factors.

Limitations of this study come from its highly selective sample population. All subjects were enrolled in NETT, a randomized trial of LVRS for patients with a predominantly emphysematous phenotype. As such, selection bias was imposed by requirements for a highly selected subset of patients with severe COPD. In addition, the mBODE was a modification of the original multidimensional index. On the other hand, the operating characteristic of the mBODE was remarkably similar with regard to prognostic ability (4) to the original index (3). In addition, the predictive ability of a greater than 1-unit change in mBODE was similar to that noted for changes in a broader spectrum of patients with COPD undergoing rehabilitation in a smaller, uncontrolled study (5). Finally, although no patients were lost to follow-up, we are missing data whenever a patient was unwilling or unable to complete any one component of the mBODE. This was particularly evident in medically treated patients. It is difficult to know if this led to any systematic bias in our reported results because the predictive ability of change in mBODE is conditional on the ability of patients to contribute data at the respective time points. Interestingly, we noted that those with missing data experienced a higher mortality than those with no change in mBODE, although those with rising mBODE generally appeared to exhibit even higher mortality.

In summary, we demonstrate that a composite index (mBODE) demonstrates short- and intermediate-term responsiveness to intervention in severe COPD. This was more evident in surgically treated than in medically treated patients. Furthermore, changes in mBODE at 6, 12, and 24 months of follow-up were predictive of subsequent mortality. An increase in mBODE of greater than 1 point proved predictive of mortality. Impor-

**Figure 2.** (Continued).

**Figure 3.** Multivariate Cox survival models comparing the predictive value of change in mBODE (modified Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) at 6, 12, and 24 months postrandomization, adjusted for sex, ethnicity, baseline age, and baseline mBODE. LVRS = lung volume reduction surgery.
tantly, the changes in the individual parameters were not as predictive of subsequent survival as individual components. These changes provide support that a short- and intermediate-term change in a multidimensional composite index may be used as a surrogate for survival in clinical trials.

**Figure 4.** Kaplan-Meier curves comparing a composite outcome of survival or increase in mBODE (modified Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) greater than 1 point between medical and surgical treatment groups. The red line reflects lung volume reduction surgery (LVRS)–treated patients, whereas the blue line reflects medically treated patients.

**Conflict of Interest Statement:** F.I.M. is a consultant for Altana Pharma and has received compensation greater than $10K. He has been a member of several advisory boards, CME committees, and the speaker’s bureau for Boehringer Ingelheim (B.I.), Stadler Sax, M.D.; Amir Sharif-Khanbeh, M.D.; and GlaxoSmithKline, compensation per company is greater than $10K. In addition, F.I.M. is an advisory board for Dey and Novartis and the speaker’s bureau for Sepacor, Schering Plough, Astra, and Pfizer, receiving less than $10K per company. F.I.M. has been an investigator for industry-sponsored studies for GSK, B.I., and Actelion. M.K.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.-C.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.L.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Z.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.E.G. received speaker’s fees of less than $50,000 from GSK, less than $15,000 from B.I., less than $10,000 from Pfizer, and less than $5,000 from Schering for 2006. J.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.L.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.-C.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. B.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. F.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.K.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. G.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Z.M. received $4,000 from AstraZeneca in 2007, $1,500 from B.I. in 2007, $2,000 from Pfizer in 2006. M.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.-C.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. B.R.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.P.F. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Z.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.E.G. received speaker’s fees of less than $50,000 from GSK, less than $15,000 from B.I., less than $10,000 from Pfizer, and less than $5,000 from Schering for 2006. J.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.L.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.-C.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. B.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. F.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.K.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. G.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Z.M. received $4,000 from AstraZeneca in 2007, $1,500 from B.I. in 2007, $2,000 from Pfizer in 2006. M.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.-C.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. B.R.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.P.F. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Z.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.E.G. received speaker’s fees of less than $50,000 from GSK, less than $15,000 from B.I., less than $10,000 from Pfizer, and less than $5,000 from Schering for 2006. J.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.L.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.-C.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. B.M. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. F.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.K.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. G.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Z.M. received $4,000 from AstraZeneca in 2007, $1,500 from B.I. in 2007, $2,000 from Pfizer in 2006. M.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

**TABLE 4. CONCORDANCE INDICES FOR (CHANGE IN) mBODE INDEX AND THREE OF ITS COMPONENTS (EXCEPT FOR BODY MASS INDEX) BY STUDY ARM AND FOR THE ENTIRE COHORT AT BASELINE AND 6, 12, AND 24 MONTHS POSTRANDOMIZATION**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Entire cohort</th>
<th>Medical Treatment Arm</th>
<th>LVRS Arm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time Since Randomization</td>
<td>6 Months</td>
<td>12 Months</td>
<td>24 Months</td>
</tr>
<tr>
<td>Entire cohort</td>
<td>n</td>
<td>1,034</td>
<td>939</td>
</tr>
<tr>
<td>mBODE</td>
<td>0.66</td>
<td>0.68</td>
<td>0.69</td>
</tr>
<tr>
<td>FEV₁</td>
<td>0.58</td>
<td>0.59</td>
<td>0.61</td>
</tr>
<tr>
<td>6MWD</td>
<td>0.61</td>
<td>0.63</td>
<td>0.64</td>
</tr>
<tr>
<td>UCSD SOBQ</td>
<td>0.64</td>
<td>0.66</td>
<td>0.65</td>
</tr>
<tr>
<td>Medical arm</td>
<td>n</td>
<td>515</td>
<td>476</td>
</tr>
<tr>
<td>mBODE</td>
<td>0.64</td>
<td>0.68</td>
<td>0.67</td>
</tr>
<tr>
<td>FEV₁</td>
<td>0.57</td>
<td>0.62</td>
<td>0.61</td>
</tr>
<tr>
<td>6MWD</td>
<td>0.59</td>
<td>0.64</td>
<td>0.63</td>
</tr>
<tr>
<td>UCSD SOBQ</td>
<td>0.61</td>
<td>0.64</td>
<td>0.65</td>
</tr>
<tr>
<td>LVRS arm</td>
<td>n</td>
<td>519</td>
<td>463</td>
</tr>
<tr>
<td>mBODE</td>
<td>0.68</td>
<td>0.68</td>
<td>0.72</td>
</tr>
<tr>
<td>FEV₁</td>
<td>0.61</td>
<td>0.61</td>
<td>0.66</td>
</tr>
<tr>
<td>6MWD</td>
<td>0.65</td>
<td>0.61</td>
<td>0.67</td>
</tr>
<tr>
<td>UCSD SOBQ</td>
<td>0.67</td>
<td>0.65</td>
<td>0.65</td>
</tr>
</tbody>
</table>

**Definition of abbreviations:** LVRS = lung volume reduction surgery; mBODE = modified BODE (Body mass index, airflow Obstruction, Dyspnea, and Exercise capacity) index; 6MWT = six-minute-walk test; UCSD SOBQ = University of California San Diego Shortness of Breath Questionnaire.

Indices are calculated based on Cox regression models adjusting for patient sex, ethnicity, and baseline age.


